Letter to the editor. Re: Cost-effectiveness analysis of disease modifying drugs (-interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R. JME 2012;15(3):424–33

Autor:	Ángel Sanz, Granda, Laura García, Jurado, Carlos Polanco, Sánchez
Rok vydání:	2012
Předmět:	Multiple Sclerosis Relapsing-Remitting Adjuvants Immunologic Humans Antineoplastic Agents Interferons Peptides
Zdroj:	Journal of medical economics. 15(6)
ISSN:	1941-837X
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::bda786812e7783d152d2aa6f8f4d9920 https://pubmed.ncbi.nlm.nih.gov/22217249 Zobrazit plný text záznamu